Results 81 to 90 of about 29,485 (291)

Bispecific antibody for lung cancer: mechanisms and clinical insights

Frontiers in Immunology
Lung cancer is a refractory malignancy. Although various therapeutic options, including targeted therapies, immune checkpoint inhibitors, and systemic chemotherapy, have significantly improved the prognosis of lung cancer patients, five-year survival ...
Wei Chen, Afang Zhou, Yunfeng Zhou
doaj   +1 more source

The assembly of single domain antibodies into bispecific decavalent molecules

, 2007
Bispecific antibodies present unique opportunities in terms of new applications for engineered antibodies. However, designing ideal bispecific antibodies remains a challenge.
Li, S., Stone, E., Shenghua Li, Tong-Sevinc, Hong, Jamshid Tanha, Hirama, Tomoko, Hong Tong-Sevinc, Tanha, Jamshid, C. Roger MacKenzie, Tomoko Hirama, Jianbing Zhang, Emily Stone, Zhang, J., MacKenzie, Colin   +13 more
core   +1 more source

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV.

, 2023
In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Wang, Lili, Dimitrov, Dimiter S, Li, Jinyao, Xu, Jiyan, Yu, Fei, Ying, Tianlei, Li, Wei, Wu, Yanling, Lu, Jun, Liang, Ruiying, Kong, Yu   +10 more
core   +1 more source

Revisiting the Carbon Footprint of Single‐Use Technologies in Biomanufacturing: A Bottom‐Up Analysis Reveals a Paradigm Shift

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The biopharmaceutical industry increasingly relies on single‐use technologies (SUT) for operational flexibility. For a long time, SUT was considered more sustainable than stainless‐steel (SST) systems due to water and energy savings. This study re‐evaluates this paradigm via a detailed bottom‐up analysis of the SUT carbon footprint at the 2000 
Jan Reiners, Katharina Bruno‐Thakur, Daina Romeo, Weronika Kuśmierczyk, Ferdinand Stückler   +4 more
wiley   +1 more source

A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus

BMC Biotechnology
Background The World Health Organization (WHO) recommends combination therapy with two non-overlapping monoclonal antibodies (mAbs) to enhance protection in Rabies post-exposure prophylaxis (PEP).
Zhigao Zhang, Jia Li, Guanfeng Lin, Shouchun Cao, Yingsong Wu   +4 more
doaj   +1 more source

Purification of anti-BSA-digoxin bispecific antibodies.

, 2013
Anti-BSA-digoxin bispecific antibodies were purified from the serum using a series of purification methods. IgG fraction was obtained using 50% saturated ammonium sulfate precipitation, followed by passing through a protein A column.
Jinming Li (128865), Wei Wang (17594), Ruihuan Xu (364030)   +2 more
core   +1 more source

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, EarlyView.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

T-cell Bispecific Antibodies Suppress Multiple Myeloma

, 2017
T-cell bispecific antibodies (TCB) targeting BCMA or FcRH5 induce T cell–mediated myeloma cell death.

core   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Antibody Conjugates via Disulfide Bridging: Towards therapeutic and diagnostic applications

, 2015
Antibodies play a prominent role in chemical and biological research and the largest application of chemical bioconjugation reagents is in the production of antibody conjugates.
Hull, EA
core